title: Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori.
abstract: OBJECTIVE
  To investigate the effect of plaunotol in combination with proton-pump inhibitors on Helicobacter pylori eradication in patients with gastric ulcer.
  
  
  METHODS
  We studied 65 H. pylori-positive gastric ulcer patients. They were randomly assigned to five treatment groups: omeprazole (group I, n = 8), lansoprazole (group II, n = 13), lansoprazole+plaunotol (group III, n = 12), lansoprazole+clarithromycin (group IV, n = 16) and lansoprazole+plaunotol+clarithromycin (group V, n = 16). Ulcer status was diagnosed by endoscopy and H. pylori status by culture, histology, a urease test and a urea breath test at baseline, and after 8 and 12 weeks. The clearance and eradication rates were compared in each group.
  
  
  RESULTS
  The healing rates in groups I-V were 100, 92, 100, 100 and 100%, respectively; clearance rates were 0, 23, 42, 50 and 75%, respectively; and eradication rates were 0, 0, 8, 38 and 69%, respectively.
  
  
  CONCLUSIONS
  Combination therapy with plaunotol is efficacious for the eradication of H. pylori in gastric ulcer patients.
authors.affiliation: Fourth Department of Internal Medicine, Hyogo College of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Fukuda
authors.forename: I
authors.initials: I
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Okui
authors.forename: Y
authors.initials: Y
authors.lastname: Tonokatsu
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004224:Diterpenes; D004359:Drug Therapy, Combination; D005233:Fatty Alcohols / Q000008:administration & dosage / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000382:microbiology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D005233:Fatty Alcohols; D017291:Clarithromycin; C047686:plaunotol